Miller S, et al. - Researchers designed this study to assess the safety and efficacy of co-initiation of treatment with ertugliflozin and sitagliptin compared with placebo alone, in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on diet and exercise. Co-initiation of ertugliflozin with sitagliptin provided a clinically meaningful improvement in glycemic control over 26 weeks in patients with T2DM inadequately controlled on diet and exercise.